{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:28:09Z","timestamp":1790162889229,"version":"4.1.0"},"reference-count":104,"publisher":"Baishideng Publishing Group Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2016]]},"DOI":"10.3748\/wjg.v22.i2.862","type":"journal-article","created":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T03:01:49Z","timestamp":1453086109000},"page":"862","source":"Crossref","is-referenced-by-count":29,"title":["Status of hepatitis C virus vaccination: Recent update"],"prefix":"10.3748","volume":"22","author":[{"given":"Kouka Saadeldin","family":"Abdelwahab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.8.3.333"},{"key":"ref2","unstructured":"Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: the viruses and their replication. Fields Virology. 5th ed Philadelphia: Lippincott-Raven Publishers; 2007;1101-1152."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, Dai X, Stanfield RL, Burton DR, Ward AB. Hepatitis C virus E2 envelope glycoprotein core structure. Science 2013;342:1090-1094.","DOI":"10.1126\/science.1243876"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/v3112127"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.22215"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/474S18a"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.05.077"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12163"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107.","DOI":"10.1126\/science.282.5386.103"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Simmonds P. Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol 2004;85:3173-3188.","DOI":"10.1099\/vir.0.80401-0"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Stumpf MP, Pybus OG. Genetic diversity and models of viral evolution for the hepatitis C virus. FEMS Microbiol Lett 2002;214:143-152.","DOI":"10.1111\/j.1574-6968.2002.tb11338.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet 2008;9:267-276.","DOI":"10.1038\/nrg2323"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00550"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014;59:318-327.","DOI":"10.1002\/hep.26744"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Forns X, Thimme R, Govindarajan S, Emerson SU, Purcell RH, Chisari FV, Bukh J. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci USA 2000;97:13318-13323.","DOI":"10.1073\/pnas.230453597"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Prentoe J, Jensen TB, Meuleman P, Serre SB, Scheel TK, Leroux-Roels G, Gottwein JM, Bukh J. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol 2011;85:2224-2234.","DOI":"10.1128\/JVI.01594-10"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002;21:5017-5025.","DOI":"10.1093\/emboj\/cdf529"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01592-10"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009;457:882-886.","DOI":"10.1038\/nature07684"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i5.654"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1301764110"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29033"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006;13:34-41.","DOI":"10.1111\/j.1365-2893.2005.00651.x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-562.","DOI":"10.1038\/nrgastro.2013.107"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03574-13"},{"key":"ref26","unstructured":"WHO factsheet: HCV vaccines, number 164. Accessed February 27, 2015. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/<\/ext-link>."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Zingaretti C, De Francesco R, Abrignani S. Why is it so difficult to develop a hepatitis C virus preventive vaccine? Clin Microbiol Infect 2014;20 Suppl 5:103-109.","DOI":"10.1111\/1469-0691.12493"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29590"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.09.001"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.09.040"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2013.00212"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.02.013"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.4RI0214-126R"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/08830180802432178"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39133"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3251"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-27340-7_10"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, Walker CM. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003;197:1645-1655.","DOI":"10.1084\/jem.20030239"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.12.010"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.017"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1114927109"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27013"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994;68:1494-1500.","DOI":"10.1128\/JVI.68.3.1494-1500.1994"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Pestka JM, Zeisel MB, Bl&auml;ser E, Sch&uuml;rmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007;104:6025-6030.","DOI":"10.1073\/pnas.0607026104"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Perotti M, Mancini N, Diotti RA, Tarr AW, Ball JK, Owsianka A, Adair R, Patel AH, Clementi M, Burioni R. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol 2008;82:1047-1052.","DOI":"10.1128\/JVI.01986-07"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Haberstroh A, Schnober EK, Zeisel MB, Carolla P, Barth H, Blum HE, Cosset FL, Koutsoudakis G, Bartenschlager R, Union A, Depla E, Owsianka A, Patel AH, Schuster C, Stoll-Keller F, Doffo&euml;l M, Dreux M, Baumert TF. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 2008;135:1719-1728.e1.","DOI":"10.1053\/j.gastro.2008.07.018"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, Wang Y, Cheslock PS, Knauber M, Olsen DB. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog 2012;8:e1002895.","DOI":"10.1371\/journal.ppat.1002895"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008;14:25-27.","DOI":"10.1038\/nm1698"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 2012;205:763-771.","DOI":"10.1093\/infdis\/jir835"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, McKeating JA. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007;132:667-678.","DOI":"10.1053\/j.gastro.2006.12.008"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, Foung S, Penin F, Dubuisson J, Voisset C. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 2007;81:8101-8111.","DOI":"10.1128\/JVI.00127-07"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)\/LDL analyzed in iodixanol density gradients. J Virol 2006;80:2418-2428.","DOI":"10.1128\/JVI.80.5.2418-2428.2006"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu MY, Alter HJ, Feinstone SM. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA 2007;104:8449-8454.","DOI":"10.1073\/pnas.0703039104"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Dreux M, Cosset FL. The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies. J Viral Hepat 2007;14 Suppl 1:68-76.","DOI":"10.1111\/j.1365-2893.2007.00919.x"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, Schwarz A, Desombere I, Roels GL, Balfe P. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008;47:17-24.","DOI":"10.1002\/hep.21959"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, Angus AG, Keck ZY, Foung SK, Pietschmann T, Rice CM. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 2009;90:48-58.","DOI":"10.1099\/vir.0.006700-0"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, Jestin JL, Brown RJ, McKeating JA, Rey FA. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology 2013;58:932-939.","DOI":"10.1002\/hep.26430"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray RB, Ray R. Hepatitis C virus proteins inhibit C3 complement production. J Virol 2012;86:2221-2228.","DOI":"10.1128\/JVI.06577-11"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Kim H, Meyer K, Di Bisceglie AM, Ray R. Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function. J Virol 2013;87:5858-5867.","DOI":"10.1128\/JVI.00174-13"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray RB, Diamond MS, Atkinson JP, Ray R. Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles. J Virol 2013;87:7902-7910.","DOI":"10.1128\/JVI.00917-13"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.791277"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kr&auml;usslich HG, Mizokami M. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-796.","DOI":"10.1038\/nm1268"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1586\/egh.12.72"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Bowen DG, Walker CM. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005;201:1709-1714.","DOI":"10.1084\/jem.20050808"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Uebelhoer L, Han JH, Callendret B, Mateu G, Shoukry NH, Hanson HL, Rice CM, Walker CM, Grakoui A. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog 2008;4:e1000143.","DOI":"10.1371\/journal.ppat.1000143"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2013.01.003"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012;337:183-186.","DOI":"10.1126\/science.1225416"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2011.630662"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Garcia A, Fernandez S, Toro F, De Sanctis JB. An overview of hepatitis C vaccines. Recent Pat Inflamm Allergy Drug Discov 2014;8:85-91.","DOI":"10.2174\/1872213X08666140704115149"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2012.673589"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-012-1564-8"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.034"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.119"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00977.x"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.08.053"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir511"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir399"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01911-14"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Lindenbach BD, Evans MJ, Syder AJ, W&ouml;lk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-626.","DOI":"10.1126\/science.1114016"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.136"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.05.007"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbt.2009.01.001"},{"key":"ref83","unstructured":"Naderi M, Gholipour N, Zolfaghari MR, Moradi Binabaj M, Yegane Moghadam A, Motalleb G. Hepatitis C virus and vaccine development. Int J Mol Cell Med 2014;3:207-215."},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Ahlen G, Nystrom J, Pult I, Frelin L, Hultgren C, Sallberg M. In vivo clearance of hepatitis C virus nonstructural 3\/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J Infect Dis 2005;192:2112-2116.","DOI":"10.1086\/498218"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2240"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.4161\/hv.23900"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002925"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002330"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2008.00959.x"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104606"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Meuleman P, Bukh J, Verhoye L, Farhoudi A, Vanwolleghem T, Wang RY, Desombere I, Alter H, Purcell RH, Leroux-Roels G. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 2011;53:755-762.","DOI":"10.1002\/hep.24171"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.01.007"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2014.12.015"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.058"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.084"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003155"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1\/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One 2013;8:e59776.","DOI":"10.1371\/journal.pone.0059776"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.009"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Alvarez-Lajonchere L, Shoukry NH, Gr&aacute; B, Amador-Ca\u00f1izares Y, Helle F, B&eacute;dard N, Guerra I, Drouin C, Dubuisson J, Gonz&aacute;lez-Horta EE. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 2009;16:156-167.","DOI":"10.1111\/j.1365-2893.2008.01058.x"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2011.00319.x"},{"key":"ref102","unstructured":"Gorzin Z, Gorzin AA, Tabarraei A, Behnampour N, Irani S, Ghaemi A. Immunogenicity evaluation of a DNA vaccine expressing the hepatitis C virus non-structural protein 2 gene in C57BL\/6 mice. Iran Biomed J 2014;18:1-7."},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Gokhale NS, Vazquez C, Horner SM. Hepatitis C Virus. Strategies to Evade Antiviral Responses. Future Virol 2014;9:1061-1075.","DOI":"10.2217\/fvl.14.89"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2014.1"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v22\/i2\/862.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T02:35:58Z","timestamp":1600050958000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v22\/i2\/862.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":104,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v22.i2.862","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}